Bictegravir/emtricitabine/tenofovir alafenamide-induced acute pancreatitis: a case report.

Abstract

We report here the case of a 32-year-old male with recent diagnosis of HIV that, 45 days after starting a single tablet regimen co-formulated with bictegravir, emtricitabine and tenofovir alafenamide (BIC/FTC/TAF), experienced severe epigastric pain radiating to the back, nausea, episodes of non-bloody non-bilious vomiting and anorexia. Laboratory examination showed a rise in lipase with no alterations in serum transaminases. Abdominal ultrasound revealed a non-homogeneous structure of the pancreatic parenchyma. A diagnosis of mild drug-related acute pancreatitis was made and BIC/FTC/TAF was immediately stopped. The association between the episode of acute pancreatitis and BIC/FTC/TAF was scored as probable according to the Naranjo causality scale.

• Authors: Agostino Riva, Dario Cattaneo, Carlo Filice, Cristina Gervasoni
• Journal: International journal of STD & AIDS (Int J STD AIDS) Vol. 31 Issue 10 Pg. 1008-1010 (09 2020) ISSN: 1758-1052 [Electronic] England
• PMID: 32693738 (Publication Type: Case Reports, Journal Article)

Chemical References

• Anti-HIV Agents
• Drug Combinations
• Heterocyclic Compounds, 4 or More Rings
• Piperazines
• Pyridones
• bictegravir, emtricitabine, tenofovir alafenamide, drug combination
• Tenofovir
• Lipase
• tenofovir alafenamide
• Emtricitabine
• Adenine
• Alanine

Topics

• Acute Disease
• Adenine (adverse effects, analogs & derivatives, therapeutic use)
• Adult
• Alanine
• Anti-HIV Agents (therapeutic use)
• Antiretroviral Therapy, Highly Active (adverse effects)
• Drug Combinations
• Drug Therapy, Combination
• Emtricitabine
• HIV Infections (drug therapy)
• Heterocyclic Compounds, 4 or More Rings (adverse effects, therapeutic use)
• Humans
• Lipase (blood)
• Male
• Pancreas (diagnostic imaging)
• Pancreatitis (chemically induced)
• Piperazines
• Pyridones
• Tenofovir (adverse effects, therapeutic use)
• Ultrasonography